All In Biotech

Drug Trial Radar · NCT00702845

To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

A Phase III, Randomized, Double-blind, Active-controlled, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 µg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference

Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 397 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

397

Actual

Start

Dec 28, 2006

Primary completion

Jul 7, 2007

Study completion Nov 15, 2007

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jun 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 36 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using daily recFSH as a reference.

Conditions

  • Infertility

Interventions

  • corifollitropin alfa (Org 36286)Drug

    100 µg corifollitropin alfa subcutaneous (SC) injection

  • recFSH (follitropin beta)Drug

    150 IU recFSH SC injection

  • gonadatropin releasing hormone (GnRH) antagonist (ganirelix)Drug

    GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day

  • human chorion gonadatropin (hCG)Drug

    hCG 5,000 IU or 10,000 IU administered SC

  • progesteroneBiological

    Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

  • placebo-recFSH (follitropin alfa)Drug

    Placebo-recFSH administered at the equivalent volume of 150 IU/day.

  • placebo-corifollitropin alfaDrug

    Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.

  • open-label recFSHBiological

    Open-label recFSH administered up to a maximum dose of 200 IU/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Cumulus-oocyte-complexes Retrieved, Per AttemptTime frame: One COS cycle with cumulus-oocyte-complex retrieval (up to a maximum total duration of 21 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.